
In today’s briefing:
- MV Australia Equal Weight Index Rebalance Preview: Potential Changes in March; Multiple Overlaps
- Quiddity Leaderboard CSI Medical Jun25: One Change to Expectations; Adjustment to the Trade
- Incyte: Can Opzelura Offset Jakafi’s $3.7B Patent Cliff by 2028?
- Terumo Corp (4543 JP): Strong Demand Drives Q3FY25 Performance; FY25 Guidance Reiterated
- Medpace: Why Biotech Firms Are Locking in Long-Term Deals With This CRO?
- Avantor Inc.: 6 Major Game-Changers Impacting Its 2025 Performance & Beyond!
- Vertex Pharmaceuticals: Pipeline Progression & Product Launches As A Substantial Catalysts For Growth Trajectory!
- BLRX: Aphexda Transition Progressing
- INAB: Continued Survival in INB-100 Trial
- Inspire Medical Systems: Will The Expansion of Inspira V Be A Game Changer?

MV Australia Equal Weight Index Rebalance Preview: Potential Changes in March; Multiple Overlaps
- With 6 days left to review cutoff, there are 2 potential adds and 3 potential deletions for the MV Australia Equal Weight Index at the March rebalance.
- Even if there are no constituent changes, capping changes will lead to one-way turnover of 3% and a round-trip trade of A$159m.
- The final list of inclusions/exclusions will depend on price movements till next Friday and whether the provider makes any significant changes to the free float of stocks in the universe.
Quiddity Leaderboard CSI Medical Jun25: One Change to Expectations; Adjustment to the Trade
- CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical theme from the Shanghai, Shenzhen and Beijing Exchanges.
- In this insight, we take a look at the potential ADDs and DELs leading the race for the semiannual index rebal event in June 2025.
- We expect up to three ADDs and three DELs for the CSI Medical Service index during this index review event based on the latest available data.
Incyte: Can Opzelura Offset Jakafi’s $3.7B Patent Cliff by 2028?
- Incyte Corporation’s recent financial and corporate update for the fourth quarter and full year 2024 showcases a year of significant growth and strategic progress.
- The company achieved a 15% increase in total revenues, reaching $4.2 billion for the year, driven by a robust 8% growth in Jakafi sales and a 50% surge in Opzelura revenues.
- The financial health of Incyte remains strong, with $2.2 billion in cash reserves and no debt, allowing the company to complete a $2 billion share repurchase program.
Terumo Corp (4543 JP): Strong Demand Drives Q3FY25 Performance; FY25 Guidance Reiterated
- Terumo Corp (4543 JP) reported record high revenue, operating profit, and net profit for both Q3FY25 and Q3 YTD. Global demand continues to expand, driven by the U.S.
- In terms of segments, TIS and blood center business drove the growth. Steady progress in pricing measures and profit improvement measures led the bottomline outperforming topline, thereby improving profitability.
- FY25 guidance implies Q4FY25 revenue of ¥238B, flat YoY and down 10% QoQ. Mainstay C&V business revenue is expected to decline 6% YoY to ¥139B due to seasonality.
Medpace: Why Biotech Firms Are Locking in Long-Term Deals With This CRO?
- Medpace Holdings, Inc. reported for the fourth quarter and full fiscal year 2024, showcasing a mixed financial environment defined by growth challenges yet significant earnings improvements.
- For the year, Medpace recorded revenues of $2.11 billion, marking an 11.8% increase from the previous year, with fourth-quarter revenues of $536.6 million, up by 7.7% year-over-year.
- These increments indicate a steady income trajectory, albeit amidst a business environment tempered by rising cancellations and decreased new business awards.
Avantor Inc.: 6 Major Game-Changers Impacting Its 2025 Performance & Beyond!
- Avantor, a global supplier of materials and services for the life sciences and advanced technology industries, reported its fourth-quarter 2024 financial results, indicating a mix of positive and challenging elements in its performance.
- Avantor noted a return to low single-digit organic growth across the enterprise, a milestone that aligns with the broader market recovery.
- The bioprocessing business, in particular, showed strong performance for a fourth consecutive quarter, achieving high single-digit organic growth.
Vertex Pharmaceuticals: Pipeline Progression & Product Launches As A Substantial Catalysts For Growth Trajectory!
- Vertex Pharmaceuticals demonstrated notable progress in its financial and operational performance for the fourth quarter and full year 2024.
- The company reported record revenues, attributed primarily to the sustained commercial success of its cystic fibrosis (CF) treatments and the initiation of CASGEVY’s launch.
- Vertex’s total product revenue for the fourth quarter reached $2.91 billion, marking a 16% increase from the prior year, while full-year revenues surpassed $11 billion, reflecting a 12% growth rate.
BLRX: Aphexda Transition Progressing
- BioLineRx is a commercial stage biopharmaceutical company with a development portfolio advancing motixafortide, a platform molecule targeting indications in stem cell mobilization (SCM) & in the treatment of advanced pancreatic cancer.
- The candidate is approved in the US for SCM and is undergoing studies for use in gene therapy and in pancreatic cancer.
- Partner Gloria Biosciences is developing motixafortide in Asia & is expected to be conducting bridging studies in the near term for SCM & longer-term studies for other indications.
INAB: Continued Survival in INB-100 Trial
- IN8Bio is a clinical-stage, oncology-focused biotechnology company using ?d T cells against solid and hematological tumors.
- Its pipeline is built on the DeltEx platform & drug-resistant immunotherapy (DRI) technology which have produced clinical candidates targeting leukemia & GBM.
- INB-100 is evaluating leukemia in a Ph1 study, while INB-200 & INB-400 are Ph1 and Ph2 assets evaluating GBM.
Inspire Medical Systems: Will The Expansion of Inspira V Be A Game Changer?
- Inspire Medical Systems demonstrated a strong performance in fiscal year 2024 with notable achievements and financial results.
- The company showed significant progress in both the U.S. and international markets, indicating a positive trajectory for its operations and market presence.
- Revenue for 2024 reached $802.8 million, marking a 28% increase from the previous year.